Last reviewed · How we verify
Pharmaconutrition
Pharmaconutrition is a Small molecule drug developed by Biruni University. It is currently in Phase 2 development.
Pharmaconutrition is an intervention studied in clinical trials for conditions such as Acute Respiratory Distress Syndrome, Myosteatosis, Sarcopenia, and Critical Illness in adults. It is one of the interventions being compared to others like ClinOleic 20% and Intralipid 20% in clinical trials, including a pilot study on its effect on lung function in Acute Respiratory Distress Syndrome (ARDS).
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pharmaconutrition |
|---|---|
| Sponsor | Biruni University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients (PHASE2)
- The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- A Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmaconutrition CI brief — competitive landscape report
- Pharmaconutrition updates RSS · CI watch RSS
- Biruni University portfolio CI
Frequently asked questions about Pharmaconutrition
What is Pharmaconutrition?
Who makes Pharmaconutrition?
What development phase is Pharmaconutrition in?
Related
- Manufacturer: Biruni University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing